Loading company
Neuroone Medical Technologies Corp
NMTC · Nasdaq · Healthcare · Medical Devices
$1.05-19.6%Sep 29 close
- 1M
- -41.0%
- 6M
- -76.6%
- 1Y
- -80.4%
- 5Y
- -95.6%
NMTC · Nasdaq · Healthcare · Medical Devices
$1.05-19.6%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $2M | $1.7M | +16.34% |
| Profit | -$2M | -$1.5M | -33.68% |
| Profit per share | -$0.28 | -$0.19 | -47.37% |
| Free Cash Flow | -$1.1M | -$1.5M | +26.91% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Neuroone Medical Technologies Corp has no earnings call transcript available.
“This quarter marked another period of revenue growth compared to 2025, with product revenue increasing 16% year-over-year to $2.0 million,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders. NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by offering diagnostic and therapeutic functions. The Company is engaged in research and development for drug delivery, basivertebral nerve ablation and spinal cord stimulation programs.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neuroone Medical Technologies Corp’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.